Genfit stock plunges 27% in one month and becomes the worst performer on the SBF 120
Genfit is accumulating losses at the start of trading, establishing itself as the worst-performing value on the SBF 120 this Tuesday morning. The decline is taking hold while the Lille-based biopharmaceutical company had recorded several favorable developments in September, including its entry into the Euronext Paris indices.
Genfit worst performer on the SBF 120, breaking through short-term moving averages
Genfit is down 3.5% during the session at €10.48, displaying the last position on the SBF 120 in a market that is nevertheless progressing slightly (CAC 40 almost stable at 8,143 points, SBF 120 up 0.07%). The decline extends a difficult sequence: the stock has lost 16% over the week and more than 27% over the month, erasing a large portion of an annual performance that remains nonetheless in very positive territory (+190% over one year). The technical configuration is deteriorated. The price is now trading at €10.48, or approximately 20.5% below the 20-day moving average (€13.19) and more than 22% below the 50-day moving average (€13.45), two averages that form a distant mobile ceiling.
The RSI falls to 32, approaching oversold territory, which reflects the exhaustion of sellers over several recent sessions without yet signaling an established floor. The former support level at €10.86 (previous close) was breached at the opening, pushing the stock toward lows from several weeks ago. The next resistance level is situated at €14.52, still very far from the current price.
Short positions in sharp increase ahead of the publication of half-year results on September 29
In parallel with the stock price decline, short positions on Genfit have progressed rapidly. According to reported declarations, two funds now cumulate 1.04% of capital sold short, a level that has appeared entirely over the last thirty days (+1.04 point in one month). This rapid rise in bearish bets signals that certain institutional investors have chosen to hedge during a period of high uncertainty for the stock, even if the absolute total remains moderate and does not in itself reflect structural pressure.
The fundamental context nevertheless provides reference points. During the publication of the first quarter of 2026 (May 21, 2026), the dynamics of Iqirvo sales emerged as support for margins, while dependence on partners for commercial development was identified as a risk. The next scheduled financial update is set for September 29 with the publication of the 2026 half-year results, which will allow measurement of the progression of Iqirvo royalties and the advancement of ongoing programs, including nangibotide acquired during the summer.
